Status of approved treatments and experimental therapies for LSDs with selected bibliography
| Therapy | Target organelle | In vitro POC | In vivo POC | Clinical trials | Regulatory approval | References |
| Enzyme replacement (ERT) | Lysosome | + | + | + | + | Brady, 2006b; Neufeld, 2011 |
| Bone marrow transplantation (BMT) | Lysosome | + | + | + | N/A | Krivit, 2002; Brady, 2006a |
| Substrate reduction therapy (SRT) | Golgi | + | + | + | + | Platt and Butters, 2004; Platt and Jeyakumar, 2008; Cox, 2010 |
| Enzyme enhancement therapy (EET) | ER/lysosome | + | − | In progress | − | Okumiya et al., 2007; Fan, 2008 |
| Gene therapy (GT) | Nucleus | + | + | In progress | − | Gritti, 2011; Tomanin et al., 2012 |
| Stop codon read-through | Nucleus | + | − | − | − | Brooks et al., 2006 |
| Calcium modulation therapy (CMT) | ER | + | + | − | − | Lloyd-Evans et al., 2008 |
| Enhanced exocytosis therapy (ExT) | Exosome | + | − | − | − | Strauss et al., 2010; Medina et al., 2011 |
| Chaperone therapy by HSp70 (CT) | Lysosome | + | − | − | − | Kirkegaard et al., 2010 |
| Proteostasis regulation therapy (PRT) | ER | + | − | − | − | Balch et al., 2008; Mu et al., 2008 |
| Cholesterol removal using cyclodextrin in NPC1 disease | Lysosome | + | + | − | − | Davidson et al., 2009; Ward et al., 2010; Aqul et al., 2011 |
| Therapy | Target organelle | In vitro POC | In vivo POC | Clinical trials | Regulatory approval | References |
| Enzyme replacement (ERT) | Lysosome | + | + | + | + | |
| Bone marrow transplantation (BMT) | Lysosome | + | + | + | N/A | |
| Substrate reduction therapy (SRT) | Golgi | + | + | + | + | |
| Enzyme enhancement therapy (EET) | ER/lysosome | + | − | In progress | − | |
| Gene therapy (GT) | Nucleus | + | + | In progress | − | |
| Stop codon read-through | Nucleus | + | − | − | − | |
| Calcium modulation therapy (CMT) | ER | + | + | − | − | |
| Enhanced exocytosis therapy (ExT) | Exosome | + | − | − | − | |
| Chaperone therapy by HSp70 (CT) | Lysosome | + | − | − | − | |
| Proteostasis regulation therapy (PRT) | ER | + | − | − | − | |
| Cholesterol removal using cyclodextrin in NPC1 disease | Lysosome | + | + | − | − |
POC, proof of concept.
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Please sign in to your personal account to gift article access.
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Gift articles remaining: --
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Gift articles remaining: --
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses.
You have reached the limit of 10 links within a 30 day period.
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.